Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Interest Coverage Ratio for the year ending December 31, 2023: -41.95

Oncopeptides AB (publ) Interest Coverage Ratio is -41.95 for the year ending December 31, 2023, a 89.00% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Oncopeptides AB (publ) Interest Coverage Ratio for the year ending December 31, 2022 was -381.42, a 74.54% change year over year.
Oncopeptides AB (publ) Interest Coverage Ratio for the year ending December 31, 2021 was -1,498.34, a -39.85% change year over year.
Oncopeptides AB (publ) Interest Coverage Ratio for the year ending December 31, 2020 was -1,071.35, a 23.49% change year over year.
Oncopeptides AB (publ) Interest Coverage Ratio for the year ending December 31, 2019 was -1,400.36, a 99.33% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years